von Willebrand Factor Antigen
The von Willebrand factor (vWF) is an adhesive multimeric glycoprotein (a protein with an attached carbohydrate). This protein promotes platelet-to-platelet and platelet-to-vessel adhesion at the site of an injury during the coagulation process. Plasma vWF also serves as a carrier protein and stabilizer for coagulation factor VIII levels. vWF is present in the blood in two separate forms: plasma vWF which reflects its synthesis and release from blood vessel endothelial (lining) cells, and platelet vWF which reflects systhesis by bone marrow megakaryocytes (platelet forming cells) and is present within the alpha granules of platelets. Platelet vWF is about 10% of the total blood vWF.
Plasma vWF antigen assay measures the plasma vWF but not the platelet vWF, and is not a functional assay. vWF function assay is usually done by the plasma ristocetin cofactor assay, and the usefulness of the vWF antigen assay is highest when combined with concurrent plasma ristocetin cofactor activity and Factor VIII coagulant activity. Genetic defects on the vWF that will impair its synthesis or function (quantitative or qualitative defects) often may result in bleeding disorders called von Willebrand Disease (vWD).
Von Willebrand Disease is the most common hereditary bleeding disorder, occurring in up to 1% of the general population. Initial tests for vWD are bleeding time, platelet count, PT and aPTT. In vWD, the platelet count and platelet morphology are generally normal. Bleeding time is usually prolonged (markedly prolonged by aspirin). The aPTT may not be prolonged if factor VIII coagulant level is >30%. Diagnosis of vWD is suggested by bleeding symptoms and family history. Initial screening tests are followed by the diagnostic tests Ristocetin cofacter (an assay for function) and vWFAg (a quantitative antigenic assay). Further tests may be necessary to distinguish the subtypes of vWD, such as vWF multimer analysis, Factor VIII assay, Factor VIII binding capacity and platelet aggregation studies (low-dose ristocetin).
- Diagnosis of von Willebrand Disease
- Differentiating von Willebrand Disease subtypes
- Differential diagnosis of von Willebrand's Disease from Hemophilia A and B
- Assist in determining hemophilia A carrier status
- Differential diagnosis of other bleeding disorders
- Monitoring the effectivness of DDAVP (desmopressin) or von Willebrand Factor concentrate therapy
Increased in:
- Inflammatory states
- Infections and sepsis
- Pregnancy or estrogen use
- Severe stress or excercise
- Vasculitis
- Liver disease
- Thrombotic thrombocytopenic purpura
- Hemolytic uremic syndrome
Decreased in:
- Hereditary von Willebrand Disease (vWD)
- Acquired von Willebrand Disease, as may be seen with Autoimmune diseases, Lymphoproliferative disorders, Monoclonal gammopathies and Hypothyroidism
- Type 1, decreased antigen and activity levels
- Type 3, undetectable antigen and activity
- Type 2, antigen level may be normal, but activity is impaired
| Blood Type | vWF Antigen (U/dL) |
| Blood type O | 50–150 |
| Blood type non-O | 90–200 |
Note: Neonates, infants, and children may have slightly elevated von Willebrand factor (vWF) antigen levels compared to adults.
Chemiluminescent immunoassay, enzyme immunoassay, enzyme-linked immunosorbent assay (ELISA).
Plasma Citrate (Light Blue).
Freeze immediately and maintain frozen until tested.
Stability
- Ambient: 4 hr
- Refrigerated: Unacceptable
- Frozen: 14 days
- J Thromb Haemost. 2013 Mar 21. [PMID:23516995]
- Haemophilia. 2008 Nov;14 Suppl 5:11-26. [PMID: 1878600]
- N Engl J Med. 2003;349:343. [PMID: 12878741]
- Mayo Clin Proc. 1991 Jun;66(6):628-33. [PMID: 2046402]
- Rev Clin Exp Hematol. 2001 Dec;5(4):335-68. [PMID: 11844133]
- N Engl J Med. 2004;351:683. [PMID: 15306670]
- Semin Thromb Hemost. 2006;32:456. [PMID: 16862518]
- Acta Haematol. 2009;121(2-3):71-84. [PMID: 1950635]
- Alan Wu. Tietz Clinical Guide to Laboratory Tests, Fourth Edition. Saunders; 4 edition (June 13, 2006). ISBN-10: 0721679757